- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04470492
Study on Prevention and Treatment of Atherosclerotic Cerebral Occlusive Disease With Remote Ischemic Conditioning
The primary objective of the study will be to determine whether remote limb ischemic conditioning (RLIC) together with conventional medication therapy compared with only medication therapy reduces the 3-month risk of composite cardio-cerebral vascular event in patients with a recent TIA or IS caused by occlusion of a cerebral artery.
After screening period, eligible patients will be randomly allocated into 2 groups.In addition, all participants receive an usual clinical therapy.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female with age from 40 to 80 years old.
- Patients with cerebral arterial occlusion which have been confirmed by CTA, MRA, or other evidence (including intracranial and extracranial arterial occlusion), and there is no indication of intervention and surgery, and at the same time the patients combined more than two risk factors for atherosclerosis.
- The entry event is acute ischemic cerebrovascular disease (TIA or cerebral infarction), of which the condition was relatively stable within 30 days of onset, and mRS≤4.
- Informed consent obtained.
Exclusion Criteria:
- Thrombolytic therapy within 24 hours prior to enrollment.
- Progressive neurological signs within 24 hours prior to enrollment.
- Cerebral venous thrombosis/stenosis.
- Intracranial arterial occlusion due to arterial dissection, Moya Moya disease; any known vasculitic disease; herpes zoster, varicella zoster or other viral vasculopathy; neurosyphilis; any other intracranial infection; any intracranial stenosis associated with cerebrospinal fluid (CSF) pleocytosis; radiation induced vasculopathy; fibromuscular dysplasia; sickle cell disease; neurofibromatosis; benign angiopathy of central nervous system; post-partum angiopathy; suspected vasospastic process, suspected recanalized embolus.
- Any of the following unequivocal cardiac source of embolism: rheumatic mitral and or aortic stenosis, prosthetic heart valves, atrial fibrillation, atrial flutter, sick sinus syndrome, left atrial myxoma, patent foramen ovale, left ventricular mural thrombus or valvular vegetation, congestive heart failure, bacterial endocarditis, or any other cardiovascular condition interfering with the participation.
- Uncontrolled severe hypertension [sitting systolic blood pressure (SBP) >180 mmHg and/or sitting diastolic blood pressure (DBP) >110 mmHg after medication].
- Patients with abnormal laboratory parameters: aspartate transaminase (AST) and/or alanine transaminase (ALT) >3×upper limit of normal range; creatinine clearance <0.6 ml/s and/or serum creatinine >265 μmol/l (>3.0 mg/dl); platelets <100×109/L.
- Any intracranial hemorrhage (parenchymal, subarachnoid, subdural, epidural) within 90 days prior to enrollment.
- Intracranial neoplasm, cerebral aneurysm or arteriovenous malformation.
- Known retinal hemorrhage or visceral bleeding within 30 days prior to enrollment.
- Severe hemostatic disorder or severe coagulation dysfunction.
- Subclavian arterial stenosis≥50% or subclavian steal syndrome.
- Extracranial stenosis ≥50%.
- Previous treatment of target lesion with a stent, angioplasty, or other mechanical device, or plan to perform one of these procedures within 12 months after enrollment.
- Major surgery (including open femoral, aortic, or carotid surgery, cardiac) within previous 30 days or scheduled in the 12 months after enrollment.
- Contraindication for remote ischemic conditioning: severe soft tissue injury, fracture, or peripheral vascular disease in the upper limbs.
- Life expectancy<3 years.
- Pregnant or breast-feeding women.
- Unwilling to be followed up or poor compliance for treatment.
- Patients being enrolled or having been enrolled in other clinical trial within 3 months prior to this clinical trial.
- Patients unsuitable for enrollment in the clinical trial according to investigators decision making.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
OTHER: Control
|
Patients will be treated with conventional medication for 3 months.
|
EXPERIMENTAL: Experiment
|
Patients will be treated with Renqiao Remote Ischemic Conditioning Device (Doctormate®) (200mmHg) twice daily and conventional medication for 3 months.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
3-month composite cardio-cerebral vascular event rate
Time Frame: During the first 3 months from randomization.
|
During the first 3 months from randomization.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Recurrence of TIA or infarction rate in the area of responsible vessel domination within 3 months
Time Frame: During the first 3 months from randomization.
|
During the first 3 months from randomization.
|
Changes in National Institutes of Health Stroke Scale(NIHSS) within 3 months
Time Frame: During the first 3 months from randomization.
|
During the first 3 months from randomization.
|
Changes in modified Rankin Scale(mRS) within 3 months
Time Frame: During the first 3 months from randomization.
|
During the first 3 months from randomization.
|
Changes in Barthel Index(BI) within 3 months
Time Frame: During the first 3 months from randomization.
|
During the first 3 months from randomization.
|
12-month composite cardio-cerebral vascular event rate
Time Frame: During the first 12 months from randomization.
|
During the first 12 months from randomization.
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RICO
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cerebral Atherosclerosis
-
Otsuka Beijing Research InstituteCompletedAtherosclerosis Cerebral InfarctionChina
-
Yinyi(Liaoning) Biotech Co., Ltd.Henan Provincial People's HospitalRecruitingCerebral Ischemia | Cerebral AtherosclerosisChina
-
Chinese PLA General HospitalRecruitingCerebral Small Vessel Diseases | ICAS - Intracranial AtherosclerosisChina
-
Capital Medical UniversityUnknownIntracranial Atherosclerosis | Chronic Cerebral IschemiaChina
-
Materia Medica HoldingCompletedCerebral AtherosclerosisRussian Federation
-
liuxingjuBeijing Municipal Science & Technology CommissionUnknownIntracranial Aneurysm | Atheroscleroses, Cerebral | Cerebrovascular StenosisChina
-
Wuhan Union Hospital, ChinaRecruitingHigh-Resolution Assessment of Extracranial Plaques in a Multiple Centers Evolocumab Randomized StudyCerebral AtherosclerosisChina
-
Maharishi International UniversityCollege of Medicine, Charles R. Drew University of Medicine and Science; Barbara...CompletedCardiovascular Disease
-
Assiut UniversityUnknownAtherosclerosis | Atheroma of Cerebral Arteries | Atheroma; Carotid Artery | Atheroma; Cerebral
-
General Hospital of Shenyang Military RegionRecruitingStroke, Ischemic | Atherosclerosis, CerebralChina
Clinical Trials on Doctormate®+Medical Management
-
Ji Xunming,MD,PhDUnknownIntracranial AtherosclerosisChina
-
Tianjin Medical University General HospitalUnknownSubcortical Vascular DementiaChina
-
Northwestern UniversityNorthShore University HealthSystemRecruitingBenign Prostatic HyperplasiaUnited States
-
Avanos MedicalCompletedSacroiliac Joint PainUnited States
-
J. MoccoUniversity at Buffalo; MOUNT SINAI HOSPITALCompletedIntracranial HemorrhageUnited States
-
Ji Xunming,MD,PhDCompletedAcute Mountain SicknessChina
-
Penumbra Inc.Active, not recruitingCerebral Hemorrhage | Intracerebral Hemorrhage | Brain Hemorrhage | Cerebral Parenchymal HemorrhageUnited States, Germany, Canada, Austria
-
Oregon Health and Science UniversityWilliam H. Hurt FoundationRecruitingObesity, ChildhoodUnited States
-
Centre Hospitalier Henri Duffaut - AvignonRecruitingChronic Myelogenous Leukemia - Chronic PhaseFrance
-
Fowler Kennedy Sport Medicine ClinicCanadian Institutes of Health Research (CIHR)Completed